View Latest Issue
Neurological complications of Sjögren syndrome and systemic lupus erythematosus (SLE) require a standardized diagnostic approach. Because these complications are a spectrum of both peripheral nervous system and central nervous system (CNS) manifestations, a broad differential diagnosis is necessary, explained Julius Birnbaum, MD, Associate Director of the Johns Hopkins Jerome L. Greene Sjögren’s Syndrome Center in Baltimore, Maryland.
Higher body mass index (BMI) in patients with rheumatoid arthritis (RA) is linked to a poorer response to a second-line biologic drug after failure of first-line treatment with a tumor necrosis factor-alpha (TNF-alpha) inhibitor, according to a study published online in Joint Bone Spine.
Pregabalin (Lyrica Capsules CV; Pfizer) did not improve pain associated with fibromyalgia in adolescents aged 12 to 17 years, according to results of a phase 4 double-blind, placebo-controlled, Pfizer-sponsored, postmarketing study reported recently. Pregabalin capsules were not significantly better than placebo in improving mean pain score.
Pulmonary arterial hypertension (PAH) can have dire consequences, especially in the context of certain connective tissue diseases (CTDs). Thus, it is important to be alert for this condition, to diagnose it accurately, and to manage it properly. That being said, pulmonary hypertension occurring in patients with CTD is often multifactorial and difficult to manage.
The diagnosis and management of psoriatic arthritis (PsA) can be challenging. It is important to make the right diagnosis and to start treating PsA early to optimize outcomes and to reduce the social and economic burden of this disease.
Shih-Yin Chen, PhD, and her colleagues analyzed annual healthcare utilization and costs related to the use of glucocorticoid (GC) drugs among 5 cohorts of adult patients with systemic lupus erythematosus (SLE).
Patients with chronic painful osteoarthritis (OA) may have a new pain killer if phase 3 clinical trials turn out to be positive. The drug in question, called tanezumab, has had a checkered history. At first, several trials showed that it was remarkably effective in people with OA, allowing them to resume activities they had not been able to participate in.
Page 2 of 2
Results 11 - 17 of 17
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology